Featured Research

from universities, journals, and other organizations

New genetic testing technology for IVF embryos

Date:
May 24, 2011
Source:
Johns Hopkins Medical Institutions
Summary:
Researchers have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities.

Researchers at the Johns Hopkins University School of Medicine have devised a new technique, which helps couples that are affected by or are carriers of genetic diseases have in vitro fertilized babies free of both the disease in question and other chromosomal abnormalities.

The results were reported in the April issue of Fertility and Sterility.

Because embryos are so small and cells contain too little DNA to do extensive testing, researchers have in the past had to limit genetic testing of IVF embryos to either looking for a specific gene mutation that is known to exist in either parent or for other types of chromosomal abnormalities such as the existence of too many or too few chromosomes (aneuploidy) or other structural chromosomal aberrations. By a method of trial and error that lasted approximately one year, Paul Brezina, M.D., M.B.A., a clinical fellow in obstetrics and gynecology and William G. Kearns, Ph.D., associate professor of obstetrics and gynecology optimized a technique they call "modified multiple displacement amplification" that allows them to amplify or make carbon copies of the DNA they obtain from an embryo obtained by in vitro fertilization, enough to do multiple tests.

"We were able to amplify the genomic DNA accurately to the point where both single-gene testing and aneuploidy screening could be done. Up till now it has only been one or the other," says Brezina.

Couples often first learn that they are carriers of a genetic disease, such as Cystic Fibrosis or Tay-Sachs, from having a previous child who is affected by the disease. Planning to have another baby, who may also be at risk for having the same disease, can be quite a daunting experience, says Brezina.

As a result, such couples have been turning to in vitro fertilization (IVF) coupled with preimplantation genetic diagnosis (PGD), genetic testing prior to implanting the embryos into the mother's uterus, to become pregnant. In PGD, which is also called single-gene testing, doctors remove either one cell from an IVF-conceived three-day old embryo, which contains only eight cells total, or a few cells from a five-day old embryo, which contains about 150 cells total. Removing more cells from the embryo is also an unviable option as it can compromise its health and development. They then test the DNA from these cells for the disease-causing genetic alteration. They then implant back into the mother only those embryos that will give rise to a baby free of the disease.

However, as much of a boon as PGD is, babies conceived in this manner are still exposed to other genetic risks, says Brezina, the most common being the gain or loss of chromosomes, a condition called aneuploidy. Aneuploidy can cause several diseases, the most commonly known of which is Down syndrome.

Brezina and Kearns applied their new modified multiple displacement technique to screen embryos from a couple where both parents were carriers for GM1 gangliosidosis, a potentially lethal disease that can cause seizures, bone malformations and mental disabilities; the couple already had one child with the disease and the mother was older and had a prior history of miscarriage. Brezina and Kearns amplified the DNA from the couple's embryos and sent some of the amplified DNA to their collaborators at the Reproductive Genetics Institute in Chicago for PGD testing for GM1 gangliosidosis. They had enough DNA leftover to test it for aneuploidy using a test called 23-chromosome microarray on embryos, a test developed by Kearns.

Of the ten IVF embryos that they tested, they found that although only two were affected by GM1 gangliosidosis, an additional three were also aneuploid, leaving them with only five healthy embryos available for transfer into the uterus. One of the healthy embryos was transferred back into the mother, who subsequently became pregnant. "The strength of this technique lies not only in its ability to detect two different kinds of genetic alterations while causing minimal harm to the embryo, but also in the speed with which it can be completed," says Kearns. "This allows the embryo to be transferred back into the mother in a timely manner."

Since the online publication of this study in December 2010, Kearns, who also directs the Shady Grove Center for Preimplantation Genetics in Rockville, MD, has offered combined PGD and aneuploidy testing to seven more couples. Five of these seven couples have achieved pregnancy with this technique and one couple is scheduled to transfer an embryo in the near future. Speaking of one of the couples, he says, "I am really happy for this couple. She is a 39-year-old woman who is a carrier for Fragile X syndrome (a genetic disease that causes mental disabilities) and had two first trimester miscarriages. We did the same methodology on her and now she is pregnant. It is spectacular."

And they aren't stopping there. Kearns and Brezina are trying to further improve existing technologies so that they can more accurately identify genetic abnormalities in IVF embryos. "IVF is only going to become more relevant as time goes on and as it gets better and better," says Brezina. He adds "The ability to know detailed information about the embryos you are putting back in, it is a powerful thing."

Authors on the paper are Paul Brezina and William Kearns of Johns Hopkins; Andrew Benner of the Shady Grove Center of Preimplanation Genetics of Rockville, Md.; and Svetlana Rechitsky, AnverKuliev, Ekaterina Pomerantseva and Dana Pauling of Reproductive Genetics Institute of Chicago, Ill.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Journal Reference:

  1. Paul R. Brezina, Andrew Benner, Svetlana Rechitsky, Anver Kuliev, Ekaterina Pomerantseva, Dana Pauling, William G. Kearns. Single-gene testing combined with single nucleotide polymorphism microarray preimplantation genetic diagnosis for aneuploidy: a novel approach in optimizing pregnancy outcome. Fertility and Sterility, 2010; DOI: 10.1016/j.fertnstert.2010.11.025

Cite This Page:

Johns Hopkins Medical Institutions. "New genetic testing technology for IVF embryos." ScienceDaily. ScienceDaily, 24 May 2011. <www.sciencedaily.com/releases/2011/05/110523161530.htm>.
Johns Hopkins Medical Institutions. (2011, May 24). New genetic testing technology for IVF embryos. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/05/110523161530.htm
Johns Hopkins Medical Institutions. "New genetic testing technology for IVF embryos." ScienceDaily. www.sciencedaily.com/releases/2011/05/110523161530.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins